Abstract 2641: The development of potent, selective RET inhibitors that target both wild-type RET and prospectively identified resistance mutations to multi-kinase inhibitors
Rami Rahal(Blueprint Medicines (United States)), Christoph Lengauer(Blueprint Medicines (United States)), Doug Wilson(Blueprint Medicines (United States)), Michelle Maynard(Froedtert Hospital), Nancy E. Kohl(United States Military Academy), Paul Fleming(Blueprint Medicines (United States)), Timothy J. Guzi(Casma Therapeutics (United States)), Michael P. Sheets(Blueprint Medicines (United States)), Nicolas Stransky(Broad Institute), Erica Evans(Blueprint Medicines (United States)), Wei Hu(Blueprint Medicines (United States)), Kevin Wilson(Blueprint Medicines (United States)), Lucian DiPietro(Blueprint Medicines (United States)), Jason D. Brubaker(Blueprint Medicines (United States)), Joseph L. Kim(Blueprint Medicines (United States))
Cited by 17
Related Papers
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
|Nature|2012|8.5k
Is a p53-Regulated Inhibitor of G2/M Progression
|Molecular Cell|1997|1.2k